Key Takeaways:
- Gubra is a privately-held biotech company founded in 2008, located in Hørsholm, Hovedstaden, Denmark.
- The company works on two primary areas: Pre-clinical contract research (CRO) services and proprietary early target and drug discovery.
- They concentrate on the metabolic space, specifically obesity, diabetes, NASH, and diabetic complications.
- Gubra stands for GUt and BRAin, the original key focus areas of their research and expertise.
- Despite its relatively short years of operation, the company has built a reputation for high quality, scientific excellence, speed, and solid teamwork.
Breaking barriers in the metabolic space is a daunting task, but one that Danish biotech start-up, Gubra, is taking on head-first. Founded in 2008 by Jacob Jelsing and Niels Vrang, Gubra is based in Hørsholm, Hovedstaden, Denmark. With a name derived from GUt and BRAin, the original focal points of their research, Gubra proves that it is intent on bringing advanced biotech innovations to the table.
Gubra specializes in pre-clinical contract research services and proprietary early target and drug discovery programs. The company has carved out a niche for itself within the realms of obesity, diabetes, NASH (non-alcoholic steatohepatitis), and diabetic complications. This comprehensive focus within the metabolic space positions the company at the forefront of advanced biotech innovation.
The major aspects that set Gubra apart are quality, scientific excellence, speed, and teamwork. They endeavor to produce the best results within the shortest possible timeframes and possess a proven track record of successful collaborations with some of the industry’s biggest players, as well as academia. Their integrated approach, combining in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, next generation sequencing, bioinformatics, and ex vivo assays, gives them a unique advantage.
Gubra has also managed to stay ahead by leveraging next-generation technologies, such as 3D imaging and next-generation sequencing. This tech-savviness, along with an emphasis on scientific excellence allows the company to continuously break new ground in the rapidly evolving field of biotech.
In terms of what lies ahead, the prospects for Gubra and the industry it operates in are promising. As health challenges continue to evolve and metastasize, there will be a perennial need for advanced biotech innovations. Players like Gubra, who are adept at leveraging cutting-edge technologies and collaborations can expect to continue thriving.
Who leads in breaking the barriers of metabolic space with advanced biotech innovations? It seems, for now, that Gubra clearly takes the lead. For more information about Gubra, visit their website at www.gubra.dk or follow them on Linkedin.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
